Nordihydroguaiaretic Acid (Masoprocol)

A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.

Also Known As:

Networked: 179 relevant articles (9 outcomes, 25 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Youngren, Jack F: 6 articles (08/2009 - 11/2005)
2.	Huang, Ru Chih C: 4 articles (05/2014 - 06/2005)
3.	Maddux, Betty A: 4 articles (08/2008 - 11/2005)
4.	Zavodovskaya, Marianna: 4 articles (08/2008 - 11/2005)
5.	Goldfine, Ira D: 4 articles (08/2008 - 11/2005)
6.	Zhu, Daling: 3 articles (09/2015 - 01/2010)
7.	Mold, David E: 3 articles (05/2014 - 06/2005)
8.	Bian, Xiu-Wu: 3 articles (08/2008 - 04/2006)
9.	Jan, Chung-Ren: 3 articles (09/2004 - 03/2002)
10.	Song, Yu: 2 articles (11/2015 - 06/2013)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2014 - "Nordihydroguaiaretic acid (NDGA), an antioxidant, was previously proven effective against cancer cells. " 06/01/2008 - "In our study we use nordihydroguaiaretic acid (NDGA), the naturally occurring lignan, to investigate whether it plays a role in the prevention and treatment of cancer by epigenetic modifications. " 11/01/2012 - "Nordihydroguaiaretic acid (NDGA) is a natural phenolic compound isolated from the creosote bush Larrea divaricata, which has anti-tumor activities both in vitro and in vivo. " 01/01/2011 - "Nordihydroguaiaretic Acid from Creosote Bush (Larrea tridentata) Mitigates 12-O-Tetradecanoylphorbol-13-Acetate-Induced Inflammatory and Oxidative Stress Responses of Tumor Promotion Cascade in Mouse Skin." 08/15/2009 - "It has been well documented that nordihydroguaiaretic acid (NDGA), a phenolic lignan isolated from the creosote bush, Larrea tridentate, has anti-cancer activity in vitro and in vivo. "
2.	Inflammation 06/21/2013 - "Because inflammation plays a key role in this secondary pathology damage, anti-inflammatory drug treatment may reduce secondary damage and protect neurons after SCI. Though nordihydroguaiaretic acid (NDGA) can inhibit inflammatory responses, its potential roles in neuroprotection and anti- inflammation in an SCI model have not been studied. " 11/01/2015 - "Our previous study proved that nordihydroguaiaretic acid (NDGA) inhibits inflammation after SCI. In this study, we tested a strategy of combining the early administration of NDGA and the transplantation of AEC-seeded CEAMC to treat SCI. The results showed that simply increasing the number of surviving AECs had no significant benefits in SCI therapy, but NDGA administration ameliorated transplanted AEC survival demonstrating the potential value of NDGA in the cellular transplantation treatment of SCI. " 09/01/2012 - "Impact on inflammation and recovery of skin barrier by nordihydroguaiaretic Acid as a protease-activated receptor 2 antagonist." 01/01/1984 - "Pretreatment of the eyes with phenidone and nordihydroguaiaretic acid (NDGA) on the other hand reduced ocular inflammation during both early and late phases. " 04/01/2013 - "Nordihydroguaiaretic acid (NDGA) and its synthetic analogues are potentially useful in treating diseases related to cancers, diabetes, viral and bacterial infections, and inflammation. "
3.	Breast Neoplasms (Breast Cancer) 11/01/2012 - "mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo." 07/01/2008 - "In the current study, we show that the phenolic compound nordihydroguaiaretic acid (NDGA) promoted cell death of trastuzumab-naive and trastuzumab-refractory HER2-overexpressing breast cancer cells. " 07/15/2007 - "Herein, we pursue the hypothesis that the structure of nordihydroguaiaretic acid (NDGA) can be refined for selective potency against the insulin-like growth factor 1 receptor (IGF-1R) as a potential therapeutic target for breast cancer while diminishing its action against other cellular targets. " 11/01/2005 - "Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells." 12/15/2007 - "Nordihydroguaiaretic acid (NDGA), a phenolic compound isolated from the creosote bush (Larrea divaricata), has anti-tumor properties against a number of malignancies, has been shown to inhibit the phosphorylation and activation of the IGF-IR in breast cancer cells, and is currently in Phase I trials for prostate cancer. "
4.	Prostatic Neoplasms (Prostate Cancer) 09/24/2004 - "Nordihydroguaiaretic acid-induced Ca2+ handling and cytotoxicity in human prostate cancer cells." 01/01/2012 - "In this study the efficacy of nordihydroguaiaretic acid (NDGA), a small molecule inhibitor of the IGF-1R, was prospectively evaluated in patients with non-metastatic hormone-sensitive prostate cancer (HSPC). " 08/01/2008 - "Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells." 09/24/2004 - "The effect of nordihydroguaiaretic acid (NDGA), a compound commonly used as a lipoxygenases inhibitor, on intracellular free Ca2+ levels ([Ca2+]i) in PC3 human prostate cancer cells was investigated. " 12/15/2007 - "Nordihydroguaiaretic acid (NDGA), a phenolic compound isolated from the creosote bush (Larrea divaricata), has anti-tumor properties against a number of malignancies, has been shown to inhibit the phosphorylation and activation of the IGF-IR in breast cancer cells, and is currently in Phase I trials for prostate cancer. "
5.	Actinic Keratosis 05/01/1991 - "Topical masoprocol appears to be useful in the treatment of actinic keratoses." 05/01/1991 - "A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck." 10/15/1993 - "Masoprocol for multiple actinic keratoses." 05/01/1991 - "Of the 113 patients who applied topical masoprocol twice a day for 14 to 28 days, there was a mean decrease in actinic keratoses from 15.0 to 5.4 and a median percent reduction from baseline actinic keratosis count of 71.4% at the 1-month follow-up visit. " 05/01/1991 - "This double-blind, vehicle-controlled, multicenter study evaluated the efficacy and safety of a new topical antineoplastic agent, masoprocol, in the treatment of actinic keratoses of the head and neck. "

Related Drugs and Biologics

1.	Lipoxygenase (Lipoxygenase-1)
2.	Arachidonic Acid (Vitamin F)
3.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
4.	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
5.	5,8,11,14-Eicosatetraynoic Acid (5,8,11,14 Eicosatetraynoic Acid)
6.	Hormones
7.	4,5- Dihydro- 1- (3- (trifluoromethyl)phenyl)- 1H- pyrazol- 3- amine
8.	phenidone
9.	Lipoxygenase Inhibitors
10.	Potassium

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Radiotherapy
4.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
5.	Ligation